The study also indicates that the reduction in CXCL13 level in CSF of patients with ALS may possibly serve as a clinical indication for ALS progression (Table 2), although further clinical studies with more patients recruited are needed to validate this idea. Here, CXCL13 is linked to amyotrophic lateral sclerosis.